HUTCHMED (China) Ltd Files April 2024 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1648257
Sentiment: neutral
Topics: reporting, sec-filing, administrative
TL;DR
HUTCHMED filed its April 6-K, confirming 20-F annual reports and Hong Kong HQ.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on April 2, 2024. This report is for the month of April 2024 and indicates that the company files annual reports under Form 20-F. The company's principal executive offices are located in Hong Kong.
Why It Matters
This filing serves as an update for investors regarding HUTCHMED's reporting status and administrative details with the SEC.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Registrant
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
- April 2, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
Which annual report form does HUTCHMED (China) Limited file?
HUTCHMED (China) Limited files its annual reports under cover of Form 20-F.
What is the principal executive office address for HUTCHMED (China) Limited?
The principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
When was the company formerly known as Hutchison China MediTech Ltd?
The company was formerly known as Hutchison China MediTech Ltd, with a date of name change on July 16, 2015.
What is the SIC code for HUTCHMED (China) Ltd?
The Standard Industrial Classification (SIC) code for HUTCHMED (China) Ltd is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 181 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-04-02 06:03:35
Filing Documents
- hcm-20240402x6k.htm (6-K) — 19KB
- hcm-20240402xex99d1.htm (EX-99.1) — 46KB
- hcm-20240402xex99d1001.jpg (GRAPHIC) — 5KB
- hcm-20240402xex99d1002.jpg (GRAPHIC) — 8KB
- 0001648257-24-000028.txt ( ) — 84KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press release relating to HUTCHMED and Innovent jointly announce NDA acceptance in China for fruquintinib combination with sintilimab for the treatment of advanced endometrial cancer with priority review status 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: April 2, 2024 3